Tags: Neuroimaging

blog

Meeting the Challenge of CTE

For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease. 

blog

Alzheimer’s Biomarkers, Explained

Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.  

announcements

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain

Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

announcements

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

Ten New Grants Support Alzheimer's Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

blog

5 Highlights from the Largest Alzheimer's Conference

Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.

blog

The Case for Dementia Screening

Healthcare professionals rarely screen patients—even those with many risk factors—for cognitive issues or dementia.

blog

The Balancing Act of Healthcare Reform

I recently saw a patient who was afraid he had Alzheimer's disease. A new scan made it easy to give him an accurate diagnosis. So why can't most patients use it? 

announcements

Medicare Panel's Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans

Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.

announcements

ADDF's Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer's Disease

The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.